- In one of the first meta-analyses to summarize QoL in patients receiving immune checkpoint inhibitors (ICIs), overall QoL did not change over time.
- Benefit at follow-up tended to be greater among recipients of nivolumab and pembrolizumab, and among patients with head and neck cancers or renal cell cancers.
Why this matters
- QoL data from patients receiving ICIs are largely limited to phase 3 trials.
- This meta-analysis yielded important quantitative information, especially about clinically relevant moderators.
- Data for 6965 adult patients with cancer were analyzed, focusing on original data from trials or prospective studies.
- Comparators were chemotherapy, placebo, other ICIs, or none.
- Typically, data from week 12 were collected.
- Funding: National Cancer Institute.
- >20,000 potential studies identified, 26 eligible.
- 9 had low risk for bias (Cochrane assessment), and 17 had high risk.
- No change of QoL overall (P=.13).
- However, QoL worsened with ICI (P=.01) and improved with durvalumab (P=.00).
- QoL also worsened in patients with melanoma, but improved in those with NSCLC, renal cell cancer, and urothelial carcinoma.
- ICI data stem from melanoma trials, which may explain worse outcomes.
- QoL at follow-up was better than comparators for nivolumab or pembrolizumab recipients.
- QoL was also better among patients with head and neck or renal cell cancer.
- Limited data from heterogeneous studies.
Follow all ESMO 2020 coverage on Univadis .